Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tavlesse
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp4143a283449d30b8e5a863d688670e88
identifier: http://ema.europa.eu/identifier
/EU/1/19/1405/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: TAVLESSE 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-4143a283449d30b8e5a863d688670e88
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/19/1405/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tavlesse
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What TAVLESSE is TAVLESSE contains the active substance fostamatinib. It specifically targets an enzyme called spleen tyrosine kinase, that plays an important part in the destruction of platelets. In this way TAVLESSE limits platelet destruction by the immune system and increases platelet count in the body. This helps reduce the risk of severe bleeding.
What TAVLESSE is used for TAVLESSE is used to treat adults with low platelet counts due to chronic immune thrombocytopenia (ITP) when an earlier treatment for ITP has not worked well enough. ITP is an autoimmune disease, in which the body s own immune system attacks and destroys platelets in the blood. Platelets are needed to help create clots and stop bleeding.
Do not take TAVLESSE
if you are allergic to fostamatinib or any of the other ingredients in this medicine (listed in section 6).
if you are pregnant.
Warnings and precautions Talk to your doctor or pharmacist before taking TAVLESSE, about all of your medical conditions, particularly if you:
have high blood pressure,
have liver problems,
are pregnant or plan to become pregnant,
are breastfeeding or plan to breastfeed.
Tell your doctor, pharmacist or nurse immediately if you get any of the following symptoms while you are taking this medicine:
if you have high blood pressure (hypertension). New or worsening high blood pressure is common in people treated with TAVLESSE and can be severe. Your doctor will check your blood pressure regularly during treatment with this medicine. If needed, your doctor may start you on blood pressure medicine or change your current medicine to treat your blood pressure. Tell your doctor or pharmacist if you get headaches, confusion, dizziness, chest pain or shortness of breath.
if your skin and eyes appear yellowish (jaundice) or if you get abdominal pain and swelling, swelling in your legs and ankles, itchy skin, abnormal dark urine, pale stool colour or bloody or tar-coloured stool, chronic fatigue, feeling or being sick in the stomach, and loss of appetite. Changes in liver function blood tests are common with this medicine. These may be symptoms of liver problems. Liver problems may occur and can be severe. Your doctor will regularly carry out blood tests to check how well your liver is working during treatment with this medicine.
if you get diarrhoea. This is common in people treated with this medicine and can be severe. Tell your doctor or pharmacist if you get diarrhoea during treatment with this medicine. Your doctor may recommend changes in your diet, drinking more water, or give an antidiarrhoeal medicine to limit your symptoms.
if you get a high fever (a sign of serious infection), chills, feel sick, or have a general feeling of being unwell. Your doctor will regularly do blood tests to check your white blood cell counts, and you may be told about a decrease in your white blood cell counts (neutropenia). Decreases in your white blood cell count are common with this medicine and can be severe. This may increase your risk of infection, including serious infections.
Children and adolescents TAVLESSE should not be used in patients less than 18 years of age. This medicine has not been studied in this age group.
Other medicines and TAVLESSE Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Taking TAVLESSE with certain other medicines may affect how the other medicines work and other medicines may affect how TAVLESSE works. In particular, tell your doctor if you are taking anything in this list:
Ketoconazole, this medicine is typically used to treat fungal infections.
Rifampicin, this medicine is typically used to treated bacterial infections.
Simvastatin and rosuvastatin, these medicines are typically used to treat high cholesterol.
Digoxin, this medicine is typically used to treat various heart conditions such as atrial fibrillation, atrial flutter and heart failure.
Midazolam, this medicine is typically used for sedation or to treat anxiety.
Anticoagulants, this medicine is typically used to prevent blood clotting.
Nelfinavir, this medicine is typically used to treat HIV infection.
Verapamil, this medicine it typically used to treat various heart conditions such as high blood pressure.
Ranitidine, this medicine is typically used to treat heart burn.
Ethinylestradiol, this medicine is typically used for birth control.
Pioglitazone, this medicine is typically used to treat type 2 diabetes.
Pregnancy, breast-feeding and fertility
Pregnancy TAVLESSE should not be used during pregnancy. It can cause harm or birth defects to your unborn baby.
If you are pregnant, if think you may be pregnant or if you are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If you are a woman who could become pregnant, you must use reliable contraception while you are taking TAVLESSE, and you must continue to use reliable contraception for at least 1 month after taking your last dose.
Contact your doctor straight away if you become pregnant while taking this medicine.
Breast-feeding TAVLESSE is not recommended while breast-feeding. You should not breastfeed during treatment with TAVLESSE and for at least 1 month after your last dose.
If you are breast-feeding, or are planning to breast-feed, ask your doctor or pharmacist for advice before taking this medicine.
Fertility
TAVLESSE may affect the ability of a woman to get pregnant and have a child. Talk to your doctor if this is a concern for you. There is no impact on males.
TAVLESSE contains sodium
TAVLESSE 100 mg film-coated tablets contains 23 mg sodium (main component of cooking/table salt) per tablet. This is equivalent to 1.2% of the recommended maximum daily dietary intake of sodium for an adult.
TAVLESSE 150 mg film-coated tablets contains 34 mg sodium (main component of cooking/table salt) per tablet. This is equivalent to 1.7% of the recommended maximum daily dietary intake of sodium for an adult.
How much to take Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Before starting treatment, your doctor will measure your platelet count.
The recommended dose of TAVLESSE is 100 mg twice daily (one tablet of 100 mg).
However, your doctor will check your platelet counts during your treatment with TAVLESSE and may change your dose as needed.
After starting treatment with TAVLESSE, the dose can be increased to 150 mg twice daily (one tablet of 150 mg) based on platelet count and tolerability. A daily dose of 300 mg (two tablets of 150 mg) daily must not be exceeded.
If you do not respond to treatment with fostamatinib, your doctor will stop treatment
If you have liver problems or high blood pressure, your doctor may start you on a lower dose. If you get serious side effects (such as high blood pressure, liver problems, diarrhoea or a decrease in white blood cell counts), your doctor may lower your dose or stop your treatment temporarily or permanently.
How to take TAVLESSE Swallow the tablets whole with water.
TAVLESSE can be taken with food or between meals.
In case of stomach upset, take the tablets with food.
If you are sick If you are sick at any time after taking TAVLESSE, do not take an additional tablet. Take your next dose at its regularly scheduled time.
If you take more TAVLESSE than you should If you take too much TAVLESSE, call your doctor or pharmacist right away or go to the nearest hospital emergency room.
If you forget to take TAVLESSE Do not take a double dose to make up for a forgotten tablet. Take your next dose at its regularly scheduled time.
If you stop taking TAVLESSE It is important to take TAVLESSE for as long as your doctor prescribes it. Do not stop taking this medicine unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects TAVLESSE may cause serious side effects. Tell your doctor immediately if you have any of the following serious side effects, either for the first time or if they get worse (see also section 2):
high fever. Fever has been associated with low levels of white blood cells (febrile neutropenia) or infection
diarrhoea
infection and inflammation of the lungs (pneumonia). Symptoms include feeling short of breath, chest pain and producing discoloured mucus
jaundice, abdominal pain and swelling, swelling in your legs and ankles, itchy skin, abnormal dark urine, pale stool colour or bloody or tar-coloured stool, chronic fatigue, feeling or being sick in the stomach, loss of appetite. These may be symptoms of liver problems.
severe increase of blood pressure that can lead to a stroke (hypertensive crisis). Symptoms are headache, confusion, dizziness.
Other side effects Besides the serious side effects mentioned above, you may also get other side effects.
Very common (may affect more than 1 in 10 people):
gastrointestinal disorders such as diarrhoea, feeling or being sick in the stomach, and frequent bowel movement
high blood pressure
abnormal blood test results showing how your liver is working
dizziness
Common (may affect up to 1 in 10 people):
low white blood cell count or neutropenia
stomach pain
chest pain
tiredness (fatigue)
flu-like symptoms
infections of the nose and throat, such as sore throat and the common cold
infection of the windpipe, such as bronchitis
taste changes
rash
headache
Reporting of side effects If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or your pharmacist. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicinal product does not require any special temperature storage conditions. Store in the original package to protect from moisture. Keep the bottle tightly closed.
Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What TAVLESSE contains
Mannitol, sodium hydrogen carbonate, sodium starch glycolate (type A), povidone (K30), magnesium stearate
Film-coating: poly(vinyl alcohol), titanium dioxide, macrogol (3350), talc, iron oxide yellow, iron oxide red
What TAVLESSE looks like and contents of the pack
TAVLESSE 100 mg film-coated tablets The tablet is round, curved on both sides with a dark orange film coat. The commercial tablets are debossed with R on one side and 100 on the reverse side. Available in bottle of 30 and 60 film-coated tablets. Each bottle has 2 desiccants. Not all pack sizes may be marketed.
TAVLESSE 150 mg film-coated tablets The tablet is oval, curved on both sides, with a light orange film coat. The commercial tablets are debossed with R on one side and 150 on the reverse side. Available in bottle of 30 and 60 film-coated tablets. Each bottle has 2 desiccants. Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer Instituto Grifols, S.A. Can Guasc, 2 - Parets del Vall s 08150 Barcelona - Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
AT/BE/BG/CY/EE/EL/ES/HR/HU/IE/LV/ LT/LU/MT/NL/RO/SI/SK/UK(NI) Instituto Grifols, S.A. Tel: +34 93 571 01 CZ Grifols S.R.O. Tel: +4202 2223 1DE Grifols Deutschland GmbH Tel: +49 69 660 593 DK/FI/IS/NO/SE Grifols Nordic AB Tel: +46 8 441 89 FR Grifols France T l: +33 (0)1 53 53 08 IT Grifols Italia S.p.A. Tel: +39 050 8755 PL Grifols Polska Sp. z o. o. Tel: +48 22 378 85 PT Grifols Portugal, Lda. Tel: +351 219 255 This leaflet was last revised in <{MM/YYYY}><{month YYYY}>.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-4143a283449d30b8e5a863d688670e88
Resource Composition:
Generated Narrative: Composition composition-en-4143a283449d30b8e5a863d688670e88
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1405/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tavlesse
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp4143a283449d30b8e5a863d688670e88
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp4143a283449d30b8e5a863d688670e88
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1405/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: TAVLESSE 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en